PharmaCons PhVC
Adina Anghel is an experienced professional in the pharmaceutical industry, currently serving as the CEO&Pharmacovigilance Managing Director at PharmaCons PhVC. Adina previously held positions such as Pharmacovigilance Director at Teva Pharmaceuticals and Pharmacovigilance Associate Director at Actavis. Adina's career also includes roles in regulatory affairs and clinical regulatory specialist. Adina holds a degree from Carol Davila University and has studied at Université d'Angers.
This person is not in any teams
PharmaCons PhVC
Globalization and free trade explosion have changed the way individuals today access medicinal products. Pharmacovigilance Drug Safety is the fundamental cornerstone for ensuring patient safety in clinical development and post authorization for medicinal products. With global regulatory authorities giving drug safety more and more importance, the need to have a robust Pharmacovigilance system in place is vital for an organization. Accurate and responsible monitoring of adverse events and risks observed during clinical development as well as post marketing is mandatory and in the best interest of patients, subscribers, payors and sponsors. However, resources and specialist know-how of marketing authorization holders might be limited, or company-internal pharmacovigilance department already suffering from highly stretched resources. The expertise and flexibility provided by PharmaCons PhVC can complement current activities or provide an entire team without the need to hire individual staff members.